



Helsingborg June 5, 2025

Press release

Aqilion Presents New Preclinical Proof-of-Concept Data for TAK1 Program

Helsingborg, June 5, 2025 – Aqilion AB today announces positive results from new studies with molecules from the company's lead series within the TAK1 program. The results demonstrate a strong disease-modifying effect in a well-established model of skin inflammation. The company will present the data and a new development strategy for the TAK1 program at the BIO 2025 conference in Boston June 16-18.

In recently conducted studies in a well-established rodent model – an imiquimod-induced skin inflammation model– Aqilion's lead substance in the TAK1 program demonstrated a significant improvement in all outcome measures. The results are superior to those achieved with corticosteroid-based positive controls. The compelling results indicate that inhibition of TAK1 applied directly to the skin, may provide significant therapeutic benefits in several severe chronic skin diseases. The company is now continuing development towards a well-characterized drug candidate, an optimized topical formulation, and preparations for IND enabling tox and Phase 1 studies.

"The results underscore that TAK1 is a highly interesting target for development of new drugs against chronic inflammation. The possibility of administering our drug candidate topically opens completely new development paths in several severe diseases caused by chronic inflammation or dysfunctional immunological reactions in the skin. We see great potential with this first-in-class, highly potent, non-steroidal treatment option for a wide range of dermatological conditions and look forward to presenting our new data at the BIO conference," says Sarah Fredriksson, CEO of Aqilion.

For more information, please contact:

Sarah Fredriksson, CEO, AQILION AB, + 46 (0)70 261 4575, sarah.fredriksson@aqilion.com

About Aqilion

Aqilion is a biotech company that focuses on developing innovative new treatments for diseases caused by chronic inflammation and dysfunctional immune reactions such as autoimmune diseases.

We identify innovative ideas that could potentially lead to new medications and refine them into commercially interesting projects. The innovation approach is based on solid scientific grounds, in disease areas where we, with reasonable assumptions, can understand the underlying biology, clinical relevance of the mechanism, potential patient benefit and the likelihood for finding a partner.

The company is mainly active in the early phases of drug discovery, from idea to proof-of-concept in clinical trials. Aqilion executes its development programs in a partly virtual organization in close collaboration with selected partners, with specific expertise in drug development.

AQILION AB (publ) is a Swedish public limited company headquartered in Helsingborg, Sweden. www.aqilion.com